Tackling Rare Skin Disorders: Basal Cell Nevus Syndrome Pipeline Innovation

DelveInsight’s 2025 report on the Basal Cell Nevus Syndrome Pipeline offers in-depth analysis of over 5 companies and more than 5 drugs in development. It includes profiles of pipeline therapies across clinical and non-clinical stages, evaluations by product type, development phase, administration method, and molecular category. The report also addresses inactive projects in this therapeutic area.

Eager to learn about the newest developments in the Basal Cell Nevus Syndrome Pipeline? Discover the treatments and studies capturing attention in the Basal Cell Nevus Syndrome Pipeline Outlook Report

Key Highlights from the Basal Cell Nevus Syndrome Pipeline Report

• On October 14, 2025, Sol-Gel Technologies Ltd. initiated a clinical study to assess the effectiveness and safety of Patidegib Gel 2% in preventing new basal cell carcinomas (BCCs) on the faces of adults with Gorlin syndrome.

• DelveInsight’s Basal Cell Nevus Syndrome Pipeline analysis showcases a dynamic field with over 5 active organizations developing more than 5 therapies for Basal Cell Nevus Syndrome management.

• Leading companies in Basal Cell Nevus Syndrome include Roche, PellePharm, Palvella Therapeutics, and others.

• Promising therapies encompass Patidegib, ASN-002, GDC-0449, Vismodegib, Aminolevulinic acid 20% topical solution, SUBA-Itraconazole, PTX-022, LDE225, and more.

Want to see which firms are spearheading progress in Basal Cell Nevus Syndrome? Explore the full pipeline details in the Basal Cell Nevus Syndrome Clinical Trials Assessment

The Basal Cell Nevus Syndrome Pipeline Report delivers a comprehensive overview of the condition, the current pipeline landscape, and evaluations of major therapies. It also identifies unmet needs in Basal Cell Nevus Syndrome care.

Understanding Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome (BCNS), also known as Nevoid Basal Cell Carcinoma Syndrome (NBCCS), Gorlin-Goltz syndrome, Gorlin syndrome, or Basal Cell Carcinoma Nevus Syndrome (BCCNS), is a rare genetic disorder marked by various developmental issues and a high risk of certain cancers, especially basal cell carcinoma. These small lesions are essentially miniature basal cell carcinomas.

Profiles of Emerging Basal Cell Nevus Syndrome Drugs

• Patidegib: PellePharm
  PellePharm is advancing patidegib, an investigational topical therapy aimed at reducing tumor load in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), along with other potential uses. In November 2018, PellePharm partnered with LEO Pharma to tackle rare skin conditions like Gorlin Syndrome and High Frequency Basal Cell Carcinoma (HF-BCC). Patidegib Topical Gel has earned Orphan Drug Designation and Breakthrough Therapy Designation for Gorlin Syndrome from the FDA, plus Orphan Drug Designation from the EMA's Committee for Orphan Medicinal Products in the EU. The drug is currently in Phase III trials for Basal Cell Nevus Syndrome.

• Vismodegib: Roche
  Vismodegib is an investigational oral inhibitor of the smoothened pathway, blocking hedgehog signaling. It is in Phase II development for Basal Cell Nevus Syndrome.

If you're following active Basal Cell Nevus Syndrome Clinical Trials, this summary is essential. Learn about the advancements in Basal Cell Nevus Syndrome Treatment Drugs

Basal Cell Nevus Syndrome Pipeline Insights

• The report offers detailed profiles of companies creating therapies for Basal Cell Nevus Syndrome, including the number of treatments each is pursuing.

• It categorizes therapeutic candidates into early, mid, and late development stages for Basal Cell Nevus Syndrome treatment.

• Companies focus on targeted drug development, with details on active and inactive (dormant or discontinued) initiatives.

• Drugs in development are analyzed by stage, administration route, target receptor, monotherapy or combination, mechanism of action, and molecular type.

• Comprehensive review of partnerships (company-to-company and company-academia), licensing deals, and funding to propel the Basal Cell Nevus Syndrome market forward.

Basal Cell Nevus Syndrome Companies

Key players include Roche, PellePharm, Palvella Therapeutics, and others.

Basal Cell Nevus Syndrome Therapeutic Assessment by Route of Administration

The report classifies pipeline drugs by delivery methods, such as:

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Basal Cell Nevus Syndrome Products by Molecule Type

Products are grouped by molecular categories, including:

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

From promising new candidates to market intelligence, the Basal Cell Nevus Syndrome Pipeline Report covers everything—explore it at Basal Cell Nevus Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Basal Cell Nevus Syndrome Pipeline Report

• Coverage: Global

• Basal Cell Nevus Syndrome Companies: Roche, PellePharm, Palvella Therapeutics, and others.

• Basal Cell Nevus Syndrome Therapies: Patidegib, ASN-002, GDC-0449, Vismodegib, Aminolevulinic acid 20% topical solution, SUBA-Itraconazole, PTX-022, LDE225, and others.

• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, or Both.

• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Stay updated in oncology research—uncover upcoming developments in the Basal Cell Nevus Syndrome Treatment landscape through this detailed analysis at Basal Cell Nevus Syndrome Emerging Drugs and Major Players

Table of Contents

* Introduction

* Executive Summary

* Basal Cell Nevus Syndrome: Overview

* Pipeline Therapeutics

* Therapeutic Assessment

* Late Stage Products (Phase III)

* Patidegib: PellePharm

* Drug profiles in the detailed report.....

* Mid Stage Products (Phase II)

* Vismodegib: Roche

* Drug profiles in the detailed report.....

* Early stage products (Phase I)

* Drug Name: Company Name

* Drug profiles in the detailed report.....

* Inactive Products

* Basal Cell Nevus Syndrome Key Companies

* Basal Cell Nevus Syndrome Key Products

* Basal Cell Nevus Syndrome- Unmet Needs

* Basal Cell Nevus Syndrome- Market Drivers and Barriers

* Basal Cell Nevus Syndrome- Future Perspectives and Conclusion

* Basal Cell Nevus Syndrome Analyst Views

* Basal Cell Nevus Syndrome Key Companies

* Appendix

About DelveInsight

DelveInsight is a premier market research and consulting firm dedicated to healthcare, equipping clients with high-quality intelligence and analysis for strategic choices. Our expert team, with extensive knowledge in life sciences and healthcare, delivers tailored solutions and global insights. Reach out for precise, current data to stay competitive.

Contact Us

Kanishk

kkumar@delveinsight.com